Abstract-Hypertension increases the risk of premature death and reduces work productivity. We estimated the burden of hypertension in Australia in terms of productivity lost over the working lifetime of the Australian population. Life table models were used to estimate excess mortality, years of life lost, and productivity-adjusted life years lost among Australians with hypertension and of working age (20 to 69 years), with simulated follow-up until age 70 years. In 2017, an estimated 4.1 million working-age Australians (25.9%) had hypertension, of whom an estimated 21.6% were treated and controlled, 17.0% were treated but uncontrolled, and 61.4% were untreated. With simulated follow-up, over 149 846 excess deaths leading to a loss of over 548 794 years of life were predicted to occur in the hypertension cohort. Hypertension also caused the loss of 609 801 productivity-adjusted life years (2.4%), equating to AUD$137.2 billion in lost gross domestic product over the working lifetime. A 25% reduction in hypertension prevalence, in line with the World Health Organisation Global Action Plan targets, would lead to 155 450 productivity-adjusted life years saved over the working lifetime, whereas the adequate treatment and control of all of those with hypertension would lead to 342 538 productivity-adjusted life years saved. This equates to AUD$34.3 billion and $76.4 billion in gross domestic product retained over the working lifetime of the cohort, respectively. Our findings highlight the considerable economic burden of hypertension in Australia and that effective strategies aimed at the prevention and adequate control of hypertension are likely to pay significant economic dividends for individuals, employers, and governments in the longer term. (Hypertension. 2019;73:777-784.
H ypertension is a common and important risk factor for cardiovascular and renal diseases, including ischemic heart disease, stroke, chronic kidney disease, and heart failure. [1] [2] [3] These costly chronic diseases account for a significant proportion of global health care expenditure. 4 Furthermore, the mortality burden associated with hypertension continues to grow, with worldwide attributable deaths increasing by 8.6% since 1990, according to the GBD study (Global Burden of Disease). 5 In Australia, the 2017/18 Australian Institute of Health and Welfare (AIHW) National Health Survey estimated that over 4.3 million Australians aged 18 years and over had hypertension (blood pressure ≥140/90 mm Hg or taking blood pressure-lowering medication). 6 Although the prevalence of hypertension is highest in older age groups, the burden of disease is potentially greater in younger populations because of increased years lived with disease and higher risk of cardiovascular and renal disease. 1, 6, 7 Furthermore, there is evidence to suggest younger people with hypertension are less likely to be aware of the condition and experience greater risk of premature mortality. 8, 9 In Australia in 2017, 96.6% of those aged 18 to 34 years with measured hypertension were unaware of their condition and untreated, compared with 56.7% of people aged 75 years and over. 6 The adequate control of hypertension among those treated is another significant challenge, and crucial for a reduction in risk of the associated cardiovascular complications. [10] [11] [12] In the 2017 AIHW National Health Survey, an estimated 40.9% of those with known hypertension were uncontrolled. 6 Hypertension is also associated with reduced productivity in the population of working age, because of work days lost to ill health (absenteeism) and reduced efficiency at work (presenteeism). 13, 14 The resulting loss of productivity can impose an economic burden on individuals, employers, and governments through reduced earnings, tax revenue, and gross domestic product (GDP). 15 For example, the American Heart Association estimated US$3.9 billion was lost to hypertension-related productivity loss in the United States in 2013. 14 In Australia, the AIHW estimated that hypertension and sequelae cost Australia ≈AUD$1.8 billion (US$1.3 billion) in 2009. 16 However, these estimates were based on direct costs relating to healthcare expenditure and did not incorporate indirect costs, including hypertension-related productivity losses.
In this study, we sought to estimate the impact of hypertension on the Australian population, both in terms of years of life lost and productivity-adjusted life years (PALYs) lost because of hypertension. PALYs are a newly developed metric akin to quality-adjusted life years, but which adjust years of life lived for productivity loss attributable to disease rather than loss of quality of life.
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Methods
All data and supporting material from this study are available from the referenced literature and detailed in Table S1 in the online-only Data Supplement.
We used life table models to assess the impact of hypertension on years of life and PALYs lost among Australians of working age. Separate sex and age (in 5-year age groups) cohorts of the Australian population aged 20 to 69 years were constructed, based on the 2017 Australian population data. 19 Age-specific mortality rates, workforce statistics, and measures of productivity were used to simulate the progression of these cohorts until death or age 70 years. First, the life table model estimated cumulative years of life and PALYs lived for the working-age population who had hypertension. Follow-up of the cohort was then resimulated with the hypothetical assumption that they did not have hypertension, with relevant changes to mortality rates and productivity. The differences in total years of life lived, and PALYs lived between the 2 cohorts reflected the impact of hypertension. The Australian standard 5% annual discount rate was applied to all years of life and PALYs lived.
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Data Sources
The key model inputs and data sources are described in Table S1 . The demographic profile of the cohort was derived from the estimated resident population of Australia in 2017. 19 Data on the prevalence of hypertension were drawn from the AIHW National Health Survey 2017-18. 6 Treatment status (treated or untreated) was determined based on the self-reported taking of hypertension medication (eg, antihypertensives, diuretics, β-blocking agents, calcium channel blockers, and agents acting on the renin-angiotensin system). Among those with treated hypertension, treated and controlled hypertension was defined as measured systolic blood pressure of <140 mm Hg and diastolic blood pressure of <90 mm Hg, and treated and uncontrolled hypertension was defined as measured systolic blood pressure of 140 mm Hg or more, or diastolic blood pressure of 90 mm Hg or more. 6, 21 Age-and sex-specific mortality rates for the Australian population were obtained from the AIHW General Record of Incidence of Mortality data. 22 In the absence of Australian mortality data specific to hypertension treatment and control status, mortality risk in the general population was attributed to those for those with and without hypertension using sex-specific estimates of the relative risk of allcause mortality associated with hypertension by treatment and control status derived from the Third National Examination and Nutritional Health Survey Linked Mortality Study. 22, 23 The details are provided in the online-only Data Supplement and Table S2 . Sex-and age-specific labor force participation in Australia from 2017 Australian Bureau of Statistics estimates were used to calculate the proportion of the population who were equivalent full-time (EFT) workers (total full-time workers and full-time equivalent workers estimated from part-time employment data). 24 Hypertension-related productivity loss was based on premature death (reducing productivity to zero for all future years) and applying a productivity index to years of life lived, which reflects the productivity of an individual as a proportion, ranging from 0 (entirely unproductive) to 1 (entirely productive), and captures the proportional loss in productivity of people with hypertension in the labor force. To estimate PALYs lived by the hypertension cohort, each year of life lived in the cohort was multiplied by the productivity index and the proportion of EFT workers. 17, 25 This is akin to multiplication of years of life lived by utilities to derive quality-adjusted life years. 18 Agespecific and sex-specific productivity indices were calculated by applying the productivity index, derived from estimates of absenteeism and presenteeism in those with controlled and uncontrolled hypertension from a study by Unmuessig et al 26 (Table S1 ) of 0.98 for those without hypertension, 0.96 for those with uncontrolled hypertension (treated or untreated), and 0.97 for those with controlled hypertension to the age-specific workforce participation rates.
The cost of lost productivity because of hypertension was estimated by assignment of a cost for each PALY, which was derived from total Australian GDP in 2017 (AUD$1.77 trillion) divided by the EFT workers in 2017 (n=10 186 032). 24, 27 The figure for 2017 was AUD$173 229, which we assumed as the economic value of each PALY. We projected temporal trends in GDP across the model time horizon using the Organisation for Economic Co-operation and Development long-term GDP forecasts, which for Australia predicted an average annual GDP growth of 2.7%.
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Sensitivity and Scenario Analyses
Secondary analyses were undertaken to assess the effect of 3 scenarios on the impact of hypertension on years of life lived and PALYs lived. The first scenario assessed the effect of a 25% reduction in current hypertension prevalence, in line with the global targets set by the World Health Organization Global Action Plan for the Prevention and Control of Noncommunicable Diseases. 29 The second scenario assessed the effect of the total hypertension cohort moving to treated and controlled status by applying the mortality rates and measures of productivity for those with treated and controlled hypertension to those with treated but uncontrolled hypertension and untreated hypertension. The third scenario combined the effects of scenarios 1 and 2 by simultaneously applying them to the hypertension cohort.
Deterministic sensitivity analyses were undertaken to assess the impact of uncertainty around key data inputs on the model outputs, the details of which are provided in the online-only Data Supplement.
Results
The prevalence of hypertension in the 15.9 million Australians aged 20 to 69 in 2017 was 25.9%, equating to 4.1 million people ( Table 1 ). The prevalence treated and controlled hypertension was 5.6%, treated but uncontrolled hypertension was 4.4%, and untreated hypertension was 15.9% which account for 21.6%, 17.0%, and 61.4% of those with hypertension, respectively.
Excess Mortality and Years of Life Lost to Hypertension
With follow-up of each cohort until age 70 years or death, an estimated 149 846 more deaths occurred in those with hypertension than in the same cohort assuming no hypertension ( Table 2; Table S3 ). This equated to 33.5% of the predicted number of total deaths among those with hypertension. We estimated that years of life lived by the current cohort of people living with hypertension in Australia would be reduced by 548 794 years, or by 1.2%, over their working lifetime (435 515 in men and 113 279 in women), compared with the same cohort assuming no hypertension ( Table 2; Table S4 ). This equated to an average of 0.13 years of life lost per person with hypertension over the working lifetime. Deaths and years of life lost were greatest in those with untreated hypertension (106 367 excess deaths and 393 019 years of life lost), followed by treated but uncontrolled hypertension (30 579 excess deaths and 109 282 years of life lost), and treated and controlled hypertension (12 900 excess deaths and 46 493 years of life lost; Table 2 ).
PALYs Lost to Hypertension
Hypertension was estimated to reduce PALYs lived by the current cohort of people living with hypertension in Australia by 609 801 PALYs (452 976 in men and 156 825 in women) over their working lifetime (Table 2; Table S5 ). This equated to a 2.4% reduction in the PALYs lived in those with hypertension (2.7% in men and 1.7% in women) and an average of 0.25 PALYs lost per EFT worker with hypertension.
Assuming a constant GDP per EFT worker of AUD$173 229, the 609 801 PALYs lost to hypertension in Australia would be associated with a loss of $137.2 billion in GDP. This is equivalent to an average GDP loss of AUD$55 272 per EFT worker with hypertension over the working lifetime. Figure shows the contribution to productivity loss of the 3 treatments and control status groups of the hypertension cohort considered in our models. The major contributors to productivity loss were untreated hypertension (78.1%) and treated but uncontrolled hypertension (15.9%), followed by treated and controlled hypertension (6.0%). Accordingly, the majority of costs associated with productivity losses were caused by untreated hypertension (AUD$107.1 billion) and treated but uncontrolled hypertension (AUD$21.8 billion) compared with treated and controlled hypertension (AUD$8.2 billion; Figure) .
Scenario and Sensitivity Analyses
In the hypothetical scenario wherein the prevalence of hypertension was reduced by 25% in line with the World Health Organization Global Action Plan targets, 37 462 deaths could be averted with 137 198 years of life and 155 450 PALYs saved, equating to AUD$34.3 billion in GDP retained over the working lifetime of the cohort (Table 3) . In an alternative hypothetical scenario, if everyone with hypertension was treated and controlled, 61 195 deaths could be averted, with 211 797 years of life and 342 538 PALYs saved, equating to $76.4 billion in GDP retained over the working lifetime (55.7% of projected productivity losses). If both hypothetical scenarios were applied simultaneously, 83 358 deaths could be averted, with 296 046 years of life and 409 354 PALYs saved, equating to AUD$91.6 billion in GDP retained over the working lifetime (66.8% of projected productivity losses; Table 3 ). *Age-and sex-specific population estimates were based on the 2017 estimated resident population of Australia.
19 †Age-and sex-specific proportion of the prevalence of hypertension by treatment and control status were based on estimates from the Australian National Health Survey 2017-18.
The model was sensitive to data inputs including productivity indices and hypertension-associated mortality risk, and model assumptions, including the annual discount rate (Table 4) . Compared with the base case, at upper and lower bounds of 95% CI around estimates of absenteeism and presenteeism, PALYs lost to hypertension were reduced and increased by 10.4%, respectively. Applying the upper and lower bounds of 95% CI around estimates of all-cause mortality risk associated with hypertension, PALYs lost were increased by 33.1% and decreased by 25.1%, respectively. At the upper and lower bounds of 95% CI around hypertension prevalence estimates, PALYs lost to hypertension were increase by 15.7% and reduced by 13.6%, respectively. Doubling the annual reduction in population mortality risk to 3.6% reduced PALYs lost by 4.7%, whereas removing all temporal trends in population mortality risk increased PALYs lost by 6.0%. Doubling the annual GDP growth rate to 5.4% lead to an increase in the estimate of GDP lost to AUD$168.7 billion, whereas removing all temporal trends in GDP decreased the estimate of GDP lost to AUD$105.6 billion. Finally, a reduction in annual discount rate to the World Health Organization standard annual discount rate of 3.0% led to a 25.6% increase in PALYs lost (Table 4) .
Discussion
The findings of our study highlight the substantial impact of hypertension on years of life lived and productivity in the Australian population. Among Australians aged 20 to 69 years with hypertension followed until age 70 years, hypertension was predicted to cause just under 150 000 excess deaths, 550 000 years of life lost, and 609 801 PALYs lost, equating to AUD$219 billion in lost GDP.
Productivity losses were accrued from a combination of premature mortality and morbidity-associated absenteeism and presenteeism while at work. In our analyses, 4.1 million Australians with hypertension aged 20 to 69 years in 2017 were estimated to experience risk of all-cause mortality PALYs indicates productivity-adjusted life years; and YLL, years of life lost. *Excess deaths are all-cause deaths observed in those with hypertension compared with the same cohort assuming no hypertension. †YLL by those with hypertension compared with the same cohort assuming no hypertension. Calculation of YLL was subject to an annual discount rate of 5%. ‡PALY lost by those with hypertension compared with the same cohort assuming no hypertension. Calculation of PALYs was subject to an annual discount rate of 5%. increased by just under a third compared with people without hypertension, incurring 149 846 excess deaths and 548 794 years of life lost over the working lifetime. This is comparable to the 30.2% of global deaths in those aged 15 to 70 years attributable to high systolic blood pressure according to GBD estimates and the Australian Burden of Disease 2015 Study which reported cardiovascular disease as the leading cause of years of life lost in Australians. 30, 31 We predicted the loss of over 600 000 PALYs in those with hypertension, which equates to a 2.4% reduction in the total number of PALYs lived by the current Australian population with hypertension. This was relatively similar to estimates of the number of PALYs lost to diabetes mellitus in a recent study in Australia (800 000 PALYs), despite the greater number of PALYs lost per person with diabetes mellitus (1.4 PALYs) compared with hypertension (0.3 PALYs). 17 This reflects the lower mortality risk and productivity losses but higher prevalence of hypertension compared with diabetes mellitus in the Australian population. However, fewer PALYs were lost to hypertension than those lost to smoking over the working lifetime in another study in Australia (2.5 million PALYs and 1.0 PALYs per smoker), largely driven by the high mortality risk associated with smoking. 25 The relative impact of hypertension on years of life and PALYs lost was similar in men and women in our model, with an average of 0.1 years of life lost and 0.3 PALYs lost per person over the working lifetime. These findings emphasize the economic importance of hypertension prevention in Australian men and women.
Our findings suggest PALYs lost in those with hypertension incurred a loss of AUD$173.2 billion in GDP over the working lifetime, demonstrating the significant economic impact of hypertension-related productivity losses. We showed that if hypertension was reduced by 25% in line with the World Health Organization Global Action Plan for the Prevention and Control of Noncommunicable Diseases, 155 450 PALYs would be retained over the working lifetime, equating to AUD$34.3 billion in GDP retained. 29 The adequate treatment and control of hypertension is also key to the minimization of productivity losses. Over two-thirds of the total hypertensionrelated excess deaths, years of life lost and PALYs lost across the working lifetime were accrued in those with untreated hypertension. Furthermore, despite the lower prevalence of treated but uncontrolled hypertension compared with treated and controlled hypertension in the population (4.4% versus 5.6%), over twice as many excess deaths (30 579 versus 12 900 deaths), years of life lost (46 493 versus 109 282 years of life lost), and PALYs lost (38 172 versus 101 378 PALYs) were accrued by those with treated but uncontrolled hypertension compared to those with treated and controlled hypertension. These findings reflected the high prevalence of untreated hypertension the Australian population and increased mortality risk and decreased work productivity associated with both untreated and uncontrolled hypertension. 1, 9, 11, 14 We demonstrated that if all Australians with hypertension were treated and controlled, over half of the projected productivity losses could be saved (342 538 PALYs), equating to AUD$76.4 billion in GDP retained. In a combined strategy leading to a 25% reduction PALYs indicates productivity-adjusted life years. *Twenty-five percent reduction in hypertension prevalence in line with the World Health Organization Global Action Plan for the Prevention and Control of Noncommunicable Diseases. 29 †As if all of those with hypertension were treated and controlled: the mortality risk and productivity index of treated and controlled hypertension applied to all of those with hypertension.
‡Combined effects of scenario 1 and 2 simultaneously were applied to the cohort with hypertension.
in hypertension prevalence and treatment and control in all remaining people with hypertension, nearly two-thirds of projected productivity losses could be saved 409 354 PALYs, equating to AUD$91.6 billion in GDP retained. Our estimates of GDP lost to hypertension are based on lost productivity only, and the direct costs of hypertension (including diagnosis, treatment, and care) are likely to have considerable economic impact. This is supported by recent research by American Heart Association, which found that productivity losses only accounted for 39.9% of total economic costs of cardiovascular disease in the United States, while other hypertension-specific studies have suggested that this figure could be as low as 21.0%. 14, 32 These findings suggest that the total economic burden of hypertension in Australia could be 2 to 4× greater than our estimates. However, the impact of hypertension on productivity is likely to vary by population depending on factors including health services, demography and labor force characteristics, and estimates may not be comparable across countries.
A major strength of our study was the use of PALYs to estimate productivity loss, which can be ascribed an intrinsic financial value. We used GDP per EFT worker to reflect the economic cost of each PALY. GDP considers a broad societal perspective and is the most commonly used measure of a country's economic well-being. Another strength was the use of contemporary age-and sex-specific estimates of hypertension prevalence, mortality risk, and labor force participation. However, our study had several limitations that warrant mention. Because of a lack of Australian-specific estimates of the productivity effects of hypertension, we used estimates from a study in the United States, which may not have been applicable to the Australian population. 26 Studies of the impact of hypertension on in work productivity and labor force participation in Australian populations are needed to refine model estimates. Hypertension prevalence was based on the national guidelines as measured systolic blood pressure of 140 mm Hg or more or diastolic blood pressure of 90 mm Hg or more and self-reported taking of hypertension medication, and untreated hypertension was based on survey measured blood pressure in the 2017 AIHW National Health Survey. 6, 21 This did not take into account recent debate around the utility of lower blood pressure thresholds for hypertension and may underestimate true hypertension in the Australian population. 33, 34 Hoare et al 34 estimated that if Australia were to lower the diagnostic threshold to 130/80 mm Hg, it would double the proportion of adults classified as having hypertension, and productivity losses could therefore be significantly higher than our estimates. However, this assumes that productivity among those with blood pressures between 130/80 mm Hg and 140/90 mm Hg are comparable to those with 140/90 mm Hg or over, which to the best of our knowledge, has not been studied. Our findings were based on modeled estimates from life tables which simulate the progress of the current cohort of people living with hypertension in Australia through to retirement, but we did not account for any incident GDP indicates gross domestic product; and PALYs, productivity-adjusted life years. *Apply (1) the lower and (2) upper bound of the 95% CI around the estimate of absenteeism and presenteeism estimates. †Apply (3) the lower and (4) upper bound of the 95% CI around the estimate of relative risk of all-cause mortality associated with hypertension. ‡Apply (5) the lower and (6) upper bound of the 95% CIs around the estimate of hypertension prevalence by treatment and control status. §Apply (7) double the annual reduction in mortality risk to 2% per year and (8) no temporal trend in population mortality risk. ‖Apply (9) double the annual growth rate in GDP to 6.4% per year and (10) no temporal trend in GDP across the model. These scenarios do not affect the number of PALYs lived but affect their assumed value over the model time horizon (GDP lost). ¶(11) applies an annual discount rate reduced to the World Health Organization standard of 3.0%.
cases of hypertension, nor movement between treatment and control status cohorts over time. We also assumed that projections in temporal trends in mortality rates and GDP growth held true across the model time horizon. However, in scenario analyses, the doubling and removal of the trend in population mortality rate affected the model output by <6%, although estimates of GDP lost changed considerably with the equivalent changes in GDP growth rate. A further limitation was that the contribution of common comorbidities (particularly obesity and diabetes mellitus) and complications (including stroke and myocardial infarction) of hypertension to productivity loss could not be distinguished.
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Perspectives
As a highly prevalent and important risk factor for cardiovascular disease, hypertension is a key driver of morbidity and mortality in the Australian population. By quantifying the economic burden of hypertension in Australia in terms of missed production opportunities, rather than health expenditure alone, our findings highlight the impact of hypertension on productivity and further stress the importance of prevention, treatment, and adequate control of hypertension. The impact of hypertension on productivity loss has potential global economic implications.
Interventions aimed at the prevention and adequate control of hypertension have the potential for economic payoff through gains in productivity. This perspective could help reframe the funding of these interventions from an expenditure to an investment. Further research is needed to assess the impact of hypertension on productivity in other populations and to describe the dynamics of the trade-off between investment in prevention and health services for hypertension and the net economic consequences, taking into account potential gains in productivity.
